We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Vertex Pharmaceuticals Inc | NASDAQ:VRTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.35 | 0.84% | 402.70 | 363.00 | 415.00 | 404.99 | 399.63 | 399.63 | 1,048,121 | 05:00:08 |
From Jan 2024 to Jan 2025
By Will Feuer
Vertex Pharmaceuticals said the U.S. Food and Drug Administration has approved its Casgevy drug for the treatment of transfusion-dependent beta thalassemia in patients 12 years and older.
Transfusion-dependent beta thalassemia is a serious, life-threatening genetic disease. Patients require lifelong treatment and significant use of health care resources, Vertex said, and the disease ultimately results in reduced life expectancy and a lower quality of life. In the U.S., the median age of death for patients living with TDT is 37 years, Vertex said.
Casgevy is a Crispr/Cas9 gene-edited cell therapy. The FDA has already approved it for sickle cell disease. It is the world's first medicine employing Crispr technology, a Nobel Prize-winning discovery that promised a powerful new tool for modifying genes to treat disease and improve crop production.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
January 16, 2024 14:52 ET (19:52 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Vertex Pharmaceuticals Chart |
1 Month Vertex Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
